Spectacle Films Utilising S.T.O.P.® Technology for Slowing Down Myopia Progression in Children
- Disease/Condition
- Myopia
- Drug/Device/Intervention
- Single vision spectacle lens
- Study type
- Interventional
- Intervention type
- device
- Primary sponsor
- nthalmic Pty Ltd
- Location
- Tianjin,Shanghai,Surat,Hyderabad,Hyderabad, China,India
- Phase
- N/A
- Start date
- Dec 01, 2023
- End date
- Sep 01, 2026
- Enrollment
- 210 participants
Axial length,Axial length
There are two parts to this trial. First, to compare the rate of myopia progression of
 spectacle films using Spatio Temporal Optic Phase (S.T.O.P.®) technology that provide a
 dynamic optical cue against single vision spectacle lenses. Second, to compare the rate of
 myopia progression of spectacle films using S.T.O.P.® technology that provide a dynamic
 optical cue against spectacle films using S.T.O.P.® technology that provide a static optical
 cue. A dynamic optical cue is one that changes, and a static optical cue is one that does not
 change.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06137560
- Type
- Device Trial
Access comprehensive clinical trial information for NCT06137560 through Pure Global AI's free database. This phase not specified trial is sponsored by nthalmic Pty Ltd and is currently Not yet recruiting. The study focuses on Myopia. Target enrollment is 210 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.